January 19, 2018
Add to Twitter   English | عربي  
Boehringer Ingelheim Demonstrates Continuous Commitment to Its Venture Fund and Fostering Innovation by More than Doubling Funding to 250 M€
• The Boehringer Ingelheim Venture Fund (BIVF) extends its investment focus to include regenerative medicine, infectious diseases and digital health

• BIVF increases its presence in the United States and adds new staff members

• Through its successful investments in immune-oncology, the BIVF has helped the company elevate its presence across the global healthcare ecosystem and establish a new focus area